GlobeNewswire·Nov 9, 2026, 9:01 AM ET

Daré Bioscience Releases Next Episode in “CEO Corner” Video Series

Daré Bioscience, Inc. released a new CEO Corner episode featuring Founder, President & CEO Sabrina Martucci Johnson discussing potential value drivers for the company's next growth phase.
The company is transitioning into a commercial-stage entity with FloraSync LF5 currently available & DARE to PLAY™ Sildenafil Cream prescription dispensing expected to begin this quarter.
The CEO Corner video is accessible at darebioscience.com/ceocorner for approximately 90 days following the November 9, 2026 release date.
Daré Bioscience aims to close gaps in women's health areas including contraception, menopause, sexual health, fertility, vaginal health, & infectious disease using peer-reviewed science.
The press release includes extensive forward-looking statements regarding product pipeline expansion, clinical milestones, regulatory strategies, & potential funding, noting significant risks such as capital needs, clinical trial outcomes, & FDA regulatory pathways.
DARE to PLAY™ Sildenafil Cream is defined as a 503B compounded drug product that is not FDA-approved for safety or effectiveness, relying on Section 503B-registered outsourcing facilities for production.
Investors are directed to review SEC filings for detailed risk factors related to the company's commercialization infrastructure, third-party dependencies, & potential delisting from the Nasdaq Capital Market.